Slakey L M, Slakey C M, Slakey D P
Department of Surgery, Tulane University Health Science Center, New Orleans, Louisiana 70112, USA.
Transplant Proc. 2010 Jun;42(5):1513-8. doi: 10.1016/j.transproceed.2009.12.076.
There is agreement that the number of organ donors and the number of organs recovered per donor are not maximized despite promotion of awareness and new guidelines for transplant teams. A single standard for donor management does not exist, in part because there is no consensus with respect to donor factors and management effect on transplant outcomes.
This retrospective study analyzed the long-term outcomes of 402 deceased donor kidney transplant recipients with respect to donor factors. This study differed from previous studies in that all recipients were treated with the same selection and immunosuppressive protocols.
Factors associated with improved graft survival included cause of death, more organs donated, and lower peak sodium (P < .01). Delayed graft function (DGF) decreased if more organs were donated, but increased when the donor was given dopamine. Recipients of donor kidneys with higher final creatinine values were more likely to show DGF (P < .01). A decrease in acute rejection episodes was observed among patients whose donors had received dopamine, donated more organs, and had a shorter time between incision and cross clamp (P < .05). Kidneys from donors with a higher final creatinine displayed fewer rejection episodes; those with a higher peak creatinine experienced more rejection episodes (P < .05).
The effect of donor variables on kidney transplant outcomes is important and may not be consistent with traditional expectations. Additional data collection and assessment of both short- and long-term transplant outcomes are critical to improve our understanding of the impact of deceased donor factors and management.
尽管开展了提高公众意识的活动并为移植团队制定了新指南,但器官捐献者的数量以及每位捐献者所获取的器官数量并未达到最大化,这一点已达成共识。目前不存在统一的供体管理标准,部分原因是对于供体因素以及管理措施对移植结果的影响尚未达成共识。
这项回顾性研究分析了402例已故供体肾移植受者与供体因素相关的长期结果。本研究与以往研究的不同之处在于,所有受者均采用相同的选择标准和免疫抑制方案进行治疗。
与移植肾存活率提高相关的因素包括死亡原因、捐献的器官更多以及峰值钠水平更低(P < 0.01)。如果捐献的器官更多,移植肾功能延迟恢复(DGF)的情况会减少,但当给供体使用多巴胺时,DGF会增加。供体肾最终肌酐值较高的受者更有可能出现DGF(P < 0.01)。在供体接受过多巴胺治疗、捐献器官更多且切口至血管阻断时间较短的患者中,急性排斥反应发作次数有所减少(P < 0.05)。来自最终肌酐值较高的供体的肾脏排斥反应发作次数较少;而峰值肌酐值较高的供体的肾脏排斥反应发作次数更多(P < 0.05)。
供体变量对肾移植结果的影响很重要,且可能与传统预期不一致。收集更多数据并评估短期和长期移植结果对于提高我们对已故供体因素及管理措施影响的理解至关重要。